News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.
The study found ciliated epithelial cells in the human endometrium undergo a sharp change in gene expression during the window of implantation.
The method, called jagged end analysis by sequencing and developed by a team in Hong Kong, relies on DNA end repair with methylated or unmethylated cytosine.
The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.
